Research article · 19 Aug 2025
Conference abstractPublished 26 Jul 2018
Biologics delivery across the blood brain barrier
California University of Science and Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
There are approximately 400 known neural disorders some of which being due to a disruption or failure (breakdown, opening, damage) of the blood brain barrier (BBB), while other disorders may still be due to unknown effects on it. Examples include: meningitis (an inflammation of the meninges or membranes surrounding the brain and spinal cord); epilepsy (chronic or acute seizures caused by inflammation); multiple sclerosis (MS - a disease of the immune system or/and the breaking down of the BBB in a section of the brain or spinal cord); Alzheimer disease (AD - a disease in which amyloid beta contained in blood plasma enter the brain and adhere to the surface of astrocytes); possibly prion and prion-like diseases such as Parkinson disease (PD) and AD; HIV encephalitis (a precursor of HIV-associated dementia in which latent HIV can cross the BBB inside circulating monocytes in the blood stream); and systemic inflammation (sterile or infectious) that may lead to effects on the brain, cause sickness behavior and induce or/and accelerate brain diseases such as MS and PD. Of interest here are those disorders requiring treatment by delivery of biologics across the BBB, more particularly, glioblastomas. It is therefore of utmost importance to grasp the difficulties encountered when attempting to deliver biologics at the right brain locations and at the right time-dose fractionations.I will first briefly review the brain diseases, particularly cerebral glioblastomas,, and describe how immune cells can deliver cancer drugs to the brain. Neutrophils, in particular, loaded with the chemotherapy drug paclitaxel (a cationic liposome) can traverse the BBB and kill residual cancer cells after tumor-resection surgery and slow the growth of new tumors (as demonstrated in mice). I will also discuss the capabilities of the method, its advantages and limitations.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Drug Designing: Open Access.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Alain L. Fymat”
